Additional European Equity News
AstraZeneca (AZN LN) - Engertu approved in the EU for post-ET breast cancer; demonstrates superiority over chemotherapy in the DESTINY-Breast06 trial with a 38% reduction in the risk of disease progression or death; Daiichi Sankyo to receive USD 125 million for approval, which comes in addition to the 2019 upfront payment. (Newswires)
BP (BP/ LN) - Co. says Chairman Helge will step down in "due course"; succession process will be led by Amanda Blanc. (Newswires)
Scor (SCR FP) - Placed under examination fo facts alleged against former Chair. (Newswires)
Santander (SAN SM) - Expects continued growth in Q1; expects CET1 rising to 12.9% in Q1. Affirms all 2025 targets. (Newswires)
THG (THG LN) - Completion of debt refinancing; EUR 445mln term loan B extended to Dec 29. (Newswires)
04 Apr 2025 - 07:07- ForexEU Research- Source: Newswires
Subscribe Now to Newsquawk
Click here for a 1 week free trial
Newsquawk provides audio news and commentary for over 15,000professional traders and brokers worldwide. Services include:
- Real-time audio coverage from 0630 to 2200 London time plus Asia-Pac 2200 to 1000 London time
- Teams of analysts covering equities, fixed income, FX, energy, and metals markets
- Real-time scrolling news service with instant analysis
- Daily and weekly pre-market research and calendars
- Video updates covering near-term key risk events & primary trading themes
- One-to-one chat with our expert analysts